ClinVar

Description

The heterozygous p.Gln1853Pro variant in CREBBP was identified in 1 individual with a neurodevelopmental disorder including delayed speech and language development, global developmental delay, intellectual disability, abnormal social behavior, hearing impairment, and abnormal facial shape via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Neurodev Study (https://www.neurodevproject.org/). Trio exome analysis showed this variant to be de novo. The p.Gln1853Pro variant in CREBBP has not been previously reported in individuals with Menke-Hennekam or Rubinstein-Taybi syndrome and was absent from large population studies. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in CREBBP in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal dominant CREBBP-related disorder. ACMG/AMP Criteria applied: PS2_Moderate, PP3_Moderate, PM2_supporting, PP2 (Richards 2015).